6/30/22 Conference Call: 36:54 Christine: Next

Quote:

---

36:54 Christine: Next question: Why isn't the company publicizing presentations and studies? Has NASH data attracted partnership? Has Amarex issue permanently damaged the BLA applications?

37:10 Scott Kelly: OK, so we certainly acknowledge being more metered and conservative in our publicity. We will be announcing important presentations and studies on a going forward basis. Regarding the NASH, about how NASH attracted partnerships, we just presented the PDFF and cT1 and biomarker data at EASL in London, just to shed some color on the importance of the EASL meeting, there were over 7,000 delegates present or online from 114 countries. There were 1,722 abstracts presented. There were only 4 poster presentations selected for a walking tour with the chairman at EASL. And We were one of those 4. I was present and I can tell you, it was well received by the scientific community. We can not comment on potential partnerships. But there are multiple opportunities for NASH and NASH HIV.

---